Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nerve sheath tumors can be a significant cause of morbidity for many patients. These include benign tumors such as schwannomas, diffuse and plexiform neurofibromas, and atypical neurofibromas, as well as the aggressive soft tissue sarcoma known as the malignant peripheral nerve sheath tumor (MPNST). Nerve sheath tumors occur sporadically and in the context of the clinical neuro-genetic tumor predisposition syndromes neurofibromatosis type 1 (NF1) and type 2 (NF2). Historically, the mainstay of treatment for nerve sheath tumors has been surgery. However, for both benign and malignant nerve sheath tumors, there is a high recurrence rate, highlighting the pressing need for novel therapies. As we have entered the genomic era, the hope is that an improved understanding of the genetics, and therefore the biology, of these tumors will ultimately lead to therapies that result in better outcomes. In this Special Issue, we include both review articles and original research related to the genomic understanding and modeling of schwannomas, plexiform and diffuse neurofibromas, atypical neurofibromas, and malignant peripheral nerve sheath tumors as well as genomic methods being developed and applied to advance our understanding of these tumors.

Medicine --- neurofibromatosis type 1 --- nerve sheath tumor --- cancer --- latent variables --- machine learning --- supervised learning --- transfer learning --- random forest --- metaVIPER --- tumor deconvolution --- neurofibromatosis --- malignant peripheral nerve sheath tumor --- MPNST --- polycomb repressive complex --- PRC2 --- NF1 --- kinase --- kinome adaptation --- kinome reprogramming --- MET --- MEK --- doxorubicin --- capmatinib --- tram --- genomics --- tumor evolution --- pathology --- next generation sequencing --- clinical genetics --- malignant peripheral nerve sheath tumors --- plexiform neurofibromas --- Schwann cells --- neurofibromatosis type 1 syndrome --- neurofibromin 1 --- genetically engineered mouse models --- heterogeneity --- CRISPR/Cas9 --- mouse models --- sarcoma --- tumor microenvironment --- neurofibromatosis 1 (NF1) --- mebendazole (MBZ) --- COX-2 inhibitor --- malignancy --- chemoprevention --- nerve sheath tumors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nerve sheath tumors can be a significant cause of morbidity for many patients. These include benign tumors such as schwannomas, diffuse and plexiform neurofibromas, and atypical neurofibromas, as well as the aggressive soft tissue sarcoma known as the malignant peripheral nerve sheath tumor (MPNST). Nerve sheath tumors occur sporadically and in the context of the clinical neuro-genetic tumor predisposition syndromes neurofibromatosis type 1 (NF1) and type 2 (NF2). Historically, the mainstay of treatment for nerve sheath tumors has been surgery. However, for both benign and malignant nerve sheath tumors, there is a high recurrence rate, highlighting the pressing need for novel therapies. As we have entered the genomic era, the hope is that an improved understanding of the genetics, and therefore the biology, of these tumors will ultimately lead to therapies that result in better outcomes. In this Special Issue, we include both review articles and original research related to the genomic understanding and modeling of schwannomas, plexiform and diffuse neurofibromas, atypical neurofibromas, and malignant peripheral nerve sheath tumors as well as genomic methods being developed and applied to advance our understanding of these tumors.

Medicine --- neurofibromatosis type 1 --- nerve sheath tumor --- cancer --- latent variables --- machine learning --- supervised learning --- transfer learning --- random forest --- metaVIPER --- tumor deconvolution --- neurofibromatosis --- malignant peripheral nerve sheath tumor --- MPNST --- polycomb repressive complex --- PRC2 --- NF1 --- kinase --- kinome adaptation --- kinome reprogramming --- MET --- MEK --- doxorubicin --- capmatinib --- tram --- genomics --- tumor evolution --- pathology --- next generation sequencing --- clinical genetics --- malignant peripheral nerve sheath tumors --- plexiform neurofibromas --- Schwann cells --- neurofibromatosis type 1 syndrome --- neurofibromin 1 --- genetically engineered mouse models --- heterogeneity --- CRISPR/Cas9 --- mouse models --- sarcoma --- tumor microenvironment --- neurofibromatosis 1 (NF1) --- mebendazole (MBZ) --- COX-2 inhibitor --- malignancy --- chemoprevention --- nerve sheath tumors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Melanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metastatic potential of this tumor, melanoma prognosis has been quite poor for a long time. In the past decade, groundbreaking discoveries in the melanoma research field have led to the development of two main treatment strategies: combination therapies targeting specific kinases or combination therapies focused on immune checkpoint inhibitors (ICIs). These treatment approaches have become the standard of care in most cancer centers and significantly improved the prognosis and overall survival of advanced melanoma patients. Nevertheless, many patients do not benefit from or even respond to these treatments. It is therefore essential to better comprehend the phenomenon of drug resistance, immune escape mechanisms, as well as to search for alternative treatment strategies. In addition, strong predictive biomarkers are desperately needed to improve clinical efficacy. The aim of this Special Issue is to present recent advances in the field of melanoma research, in which the abovementioned areas represent the primary focus, and other relevant themes are also discussed.

Public health & preventive medicine --- melanoma --- targeted therapies --- BRAF --- druggable mutations --- real-time PCR --- NGS assay --- immune escape --- microRNA --- transporter associated with antigen processing --- incidence --- population-based study --- epidemiology --- Spain --- skin cancer --- single-cell transcriptome sequencing --- treatment response --- pseudotime analysis --- treatment --- ubiquitination --- miRNAs --- embryogenesis --- melanoblasts --- melanoblast --- NF1 --- transcriptome --- RNAseq --- Trp-1 --- metastasis --- animal models --- lung --- mice

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Melanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metastatic potential of this tumor, melanoma prognosis has been quite poor for a long time. In the past decade, groundbreaking discoveries in the melanoma research field have led to the development of two main treatment strategies: combination therapies targeting specific kinases or combination therapies focused on immune checkpoint inhibitors (ICIs). These treatment approaches have become the standard of care in most cancer centers and significantly improved the prognosis and overall survival of advanced melanoma patients. Nevertheless, many patients do not benefit from or even respond to these treatments. It is therefore essential to better comprehend the phenomenon of drug resistance, immune escape mechanisms, as well as to search for alternative treatment strategies. In addition, strong predictive biomarkers are desperately needed to improve clinical efficacy. The aim of this Special Issue is to present recent advances in the field of melanoma research, in which the abovementioned areas represent the primary focus, and other relevant themes are also discussed.

Public health & preventive medicine --- melanoma --- targeted therapies --- BRAF --- druggable mutations --- real-time PCR --- NGS assay --- immune escape --- microRNA --- transporter associated with antigen processing --- incidence --- population-based study --- epidemiology --- Spain --- skin cancer --- single-cell transcriptome sequencing --- treatment response --- pseudotime analysis --- treatment --- ubiquitination --- miRNAs --- embryogenesis --- melanoblasts --- melanoblast --- NF1 --- transcriptome --- RNAseq --- Trp-1 --- metastasis --- animal models --- lung --- mice

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Conflict of laws --- Contrats (Droit international privé) --- Droit international privé --- Contracts --- 340.9 --- Nf1.g --- Choice of law --- Intermunicipal law --- International law, Private --- International private law --- Private international law --- Law --- Legal polycentricity --- Agreements --- Contract law --- Contractual limitations --- Limitations, Contractual --- Commercial law --- Legal instruments --- Obligations (Law) --- Juristic acts --- Liberty of contract --- Third parties (Law) --- Civil law --- Law and legislation --- Contrats (Droit international privé) --- Droit international privé